Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of oxycodone sustained-release tablets for solid tumor-related cancer pain
ChiCTR2600132163Phase 4Not yet recruiting
- Sponsor
- Nanxishan Hospital
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of oxycodone in cancer pain, sponsored by Nanxishan Hospital. Primary endpoint: Effective rate of pain relief at week 4. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
oxycodone
03
Conditions
cancer pain
Beyond the preview
Go deeper on ChiCTR2600132163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132163.